Short stature, obesity, and growth hormone deficiency in pseudohypoparathyroidism type 1a

Emily L. Germain-Lee

Research output: Contribution to journalArticle

Abstract

Albright hereditary osteodystrophy (AHO) is a genetic disorder caused by heterozygous inactivating mutations in GNAS, the gene that encodes the α-chain of Gs (G"s). This syndrome is associated with short stature, obesity, brachydactyly, and subcutaneous ossifications. Patients with GNAS mutations on maternally-inherited alleles are resistant to multiple G-protein-coupled hormones, including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), luteinizing hormone/follicle-stimulating hormone (LH/FSH), and glucagon. This variant of AHO, termed pseudohypoparathyroidism (PHP) type 1a, is due to tissue-specific paternal imprinting of Gαs. We investigated whether patients with PHP type 1a exhibited evidence of resistance to growth hormone releasing hormone (GHRH) (1), another hormone requiring Gαs function. In addition, Gas transcripts are imprinted in the pituitary somatotrophs responsible for growth hormone (GH) secretion which could thereby influence GHRH-dependent stimulation of somatotrophs. We therefore hypothesized that patients with PHP type 1a may be GH deficient which could contribute to the obesity and short stature in this condition. We found that GH deficiency is common in PHP type 1a (69%) with a prevalence that is much greater than in the general population (0.03%). We propose that GH status be evaluated in all patients with this condition. Treatment with recombinant GH could lead to improvements in height in children, as well as other physical (eg, obesity, hyperlipidemia, osteoporosis, reduced renal function) and psychological (fatigue and diminished sense of well-being) parameters in GH-deficient PHP type 1a patients of all ages.

Original languageEnglish (US)
Pages (from-to)318-327
Number of pages10
JournalPediatric Endocrinology Reviews
Volume3
Issue numberSUPPL. 2
StatePublished - Apr 2006

Fingerprint

Pseudohypoparathyroidism
Growth Hormone
Obesity
Somatotrophs
Growth Hormone-Releasing Hormone
Brachydactyly
Hormones
Mutation
Inborn Genetic Diseases
Follicle Stimulating Hormone
Thyrotropin
Luteinizing Hormone
Hyperlipidemias
Glucagon
Parathyroid Hormone
GTP-Binding Proteins
Osteogenesis
Osteoporosis
Fatigue
Gases

Keywords

  • Albright Hereditary Osteodystrophy
  • G Protein
  • GHRH Resistance
  • GNAS
  • Growth Hormone Deficiency
  • Pseudohypoparathyroidism

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Short stature, obesity, and growth hormone deficiency in pseudohypoparathyroidism type 1a. / Germain-Lee, Emily L.

In: Pediatric Endocrinology Reviews, Vol. 3, No. SUPPL. 2, 04.2006, p. 318-327.

Research output: Contribution to journalArticle

@article{f5927b6a6a844a1d9209fdd85b2cb6d3,
title = "Short stature, obesity, and growth hormone deficiency in pseudohypoparathyroidism type 1a",
abstract = "Albright hereditary osteodystrophy (AHO) is a genetic disorder caused by heterozygous inactivating mutations in GNAS, the gene that encodes the α-chain of Gs (G{"}s). This syndrome is associated with short stature, obesity, brachydactyly, and subcutaneous ossifications. Patients with GNAS mutations on maternally-inherited alleles are resistant to multiple G-protein-coupled hormones, including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), luteinizing hormone/follicle-stimulating hormone (LH/FSH), and glucagon. This variant of AHO, termed pseudohypoparathyroidism (PHP) type 1a, is due to tissue-specific paternal imprinting of Gαs. We investigated whether patients with PHP type 1a exhibited evidence of resistance to growth hormone releasing hormone (GHRH) (1), another hormone requiring Gαs function. In addition, Gas transcripts are imprinted in the pituitary somatotrophs responsible for growth hormone (GH) secretion which could thereby influence GHRH-dependent stimulation of somatotrophs. We therefore hypothesized that patients with PHP type 1a may be GH deficient which could contribute to the obesity and short stature in this condition. We found that GH deficiency is common in PHP type 1a (69{\%}) with a prevalence that is much greater than in the general population (0.03{\%}). We propose that GH status be evaluated in all patients with this condition. Treatment with recombinant GH could lead to improvements in height in children, as well as other physical (eg, obesity, hyperlipidemia, osteoporosis, reduced renal function) and psychological (fatigue and diminished sense of well-being) parameters in GH-deficient PHP type 1a patients of all ages.",
keywords = "Albright Hereditary Osteodystrophy, G Protein, GHRH Resistance, GNAS, Growth Hormone Deficiency, Pseudohypoparathyroidism",
author = "Germain-Lee, {Emily L.}",
year = "2006",
month = "4",
language = "English (US)",
volume = "3",
pages = "318--327",
journal = "Pediatric Endocrinology Reviews",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Short stature, obesity, and growth hormone deficiency in pseudohypoparathyroidism type 1a

AU - Germain-Lee, Emily L.

PY - 2006/4

Y1 - 2006/4

N2 - Albright hereditary osteodystrophy (AHO) is a genetic disorder caused by heterozygous inactivating mutations in GNAS, the gene that encodes the α-chain of Gs (G"s). This syndrome is associated with short stature, obesity, brachydactyly, and subcutaneous ossifications. Patients with GNAS mutations on maternally-inherited alleles are resistant to multiple G-protein-coupled hormones, including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), luteinizing hormone/follicle-stimulating hormone (LH/FSH), and glucagon. This variant of AHO, termed pseudohypoparathyroidism (PHP) type 1a, is due to tissue-specific paternal imprinting of Gαs. We investigated whether patients with PHP type 1a exhibited evidence of resistance to growth hormone releasing hormone (GHRH) (1), another hormone requiring Gαs function. In addition, Gas transcripts are imprinted in the pituitary somatotrophs responsible for growth hormone (GH) secretion which could thereby influence GHRH-dependent stimulation of somatotrophs. We therefore hypothesized that patients with PHP type 1a may be GH deficient which could contribute to the obesity and short stature in this condition. We found that GH deficiency is common in PHP type 1a (69%) with a prevalence that is much greater than in the general population (0.03%). We propose that GH status be evaluated in all patients with this condition. Treatment with recombinant GH could lead to improvements in height in children, as well as other physical (eg, obesity, hyperlipidemia, osteoporosis, reduced renal function) and psychological (fatigue and diminished sense of well-being) parameters in GH-deficient PHP type 1a patients of all ages.

AB - Albright hereditary osteodystrophy (AHO) is a genetic disorder caused by heterozygous inactivating mutations in GNAS, the gene that encodes the α-chain of Gs (G"s). This syndrome is associated with short stature, obesity, brachydactyly, and subcutaneous ossifications. Patients with GNAS mutations on maternally-inherited alleles are resistant to multiple G-protein-coupled hormones, including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), luteinizing hormone/follicle-stimulating hormone (LH/FSH), and glucagon. This variant of AHO, termed pseudohypoparathyroidism (PHP) type 1a, is due to tissue-specific paternal imprinting of Gαs. We investigated whether patients with PHP type 1a exhibited evidence of resistance to growth hormone releasing hormone (GHRH) (1), another hormone requiring Gαs function. In addition, Gas transcripts are imprinted in the pituitary somatotrophs responsible for growth hormone (GH) secretion which could thereby influence GHRH-dependent stimulation of somatotrophs. We therefore hypothesized that patients with PHP type 1a may be GH deficient which could contribute to the obesity and short stature in this condition. We found that GH deficiency is common in PHP type 1a (69%) with a prevalence that is much greater than in the general population (0.03%). We propose that GH status be evaluated in all patients with this condition. Treatment with recombinant GH could lead to improvements in height in children, as well as other physical (eg, obesity, hyperlipidemia, osteoporosis, reduced renal function) and psychological (fatigue and diminished sense of well-being) parameters in GH-deficient PHP type 1a patients of all ages.

KW - Albright Hereditary Osteodystrophy

KW - G Protein

KW - GHRH Resistance

KW - GNAS

KW - Growth Hormone Deficiency

KW - Pseudohypoparathyroidism

UR - http://www.scopus.com/inward/record.url?scp=33646230544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646230544&partnerID=8YFLogxK

M3 - Article

C2 - 16675931

AN - SCOPUS:33646230544

VL - 3

SP - 318

EP - 327

JO - Pediatric Endocrinology Reviews

JF - Pediatric Endocrinology Reviews

SN - 1565-4753

IS - SUPPL. 2

ER -